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OBJECTIVE:  The  influence  of  a  macrolide  antibiotic,
roxithromycin  (RXM),  on  co-stimulatory  molecule
expression was examined in vitro and in vivo.
Materials  and methods: Spleen cells obtained from
BALB/c mice 10 days after immunization with 8.0 m g
of  hemocyanin  absorbed  to  4.0mg  of  aluminum
hydroxide  were  cultured  in  the  presence  of
100.0 m g/ml  of hemocyanin  and various concentra-
tions of RXM. We first examined the influence of RXM
on  cell  activation  by  examining  the  proliferative
response of cells and cytokine production. We also
examined  the  influence  of  RXM  on  co-stimulatory
molecule  (CD40,  CD80  and  CD86)  expressions  on
cultured splenic B-lymphocytes  induced by in vitro
antigenic  stimulation  using  flow  cytometry.  In  the
second  part  of  experiments,  non-immunized  and
immunized mice were treated orally with 2.5mg/kg
of  RXM  once  a  day  for  4  or  8  weeks.  Splenic  B
lymphocytes  were  obtained  from  these  mice  24h
after  antigenic  challenge, and  co-stimulatory  mole-
cule expressions were examined by flow cytometer.
Results: Cell activation induced by in vitro antigenic
stimulation was suppressed by RXM when cells were
cultured in the presence of more than 5.0 m g/ml of
the  agent.  Addition  of  RXM  at  a  concentration  of
5.0m g/ml into cell cultures also suppressed co-stim-
ulatory molecule (CD40, CD80 and CD86) expressions
on splenic B lymphocytes,  which was enhanced by
antigenic stimulation in vitro. Oral RXM administra-
tion for 4 weeks clearly suppressed the enhancement
of  CD40  and CD86  (but  not  CD80)  expressions  on
splenic B lymphocytes induced by antigenic stimula-
tion in vivo. This suppressive activity of RXM on co-
stimulatory molecule (CD40 and CD86) expressions
was further strengthened by the treatment of mice for
8  weeks.  Long-term  treatment  with  oral  RXM  also
suppressed CD80  expressions, which  was  not  sup-
pressed by 4-week treatment.
Conclusion:  The  present  results  suggest  that  RXM
exerts  its  immunomodulating  effects  through  sup-
pression  of  both  cell  activation  and  co-stimulatory
molecule expressions induced by antigenic stimula-
tion.  These  suppressive  activities  of  RXM  might
contribute, in part, to the therapeutic mode of action
of RXM on inflammatory diseases.
Key  words:  Roxithromycin,  Mouse,  Splenic  B  lympho-
cytes,  Co-stimulatory  molecule,  Inhibition,  In  vitro,  In
vivo.
Introduction
Long-term administration of 14-membered macrolide
antibiotics has been reported to favorably modify the
clinical conditions of chronic inflammatory diseases
including  chronic sinusitis, diffuse  panbronchiolitis,
and  bronchial  asthma.1–5 This  treatment  is  called
macrolide  therapy  and  is  used  frequently  in  the
treatment  of  inflammatory  diseases,  especially  in
Japan.4,5 More  recently,  clinical  trial  therapy  in
England revealed that long-term administration (more
than 3 months) of azithromycin, a newly synthesized
macrolide antibiotic, into patients with cyctic fibrosis
can improve lung functions.6,7
Much  effort  has  been  made  to  understand  the
mechanisms  underlying  the  efficacy  of  macrolide
therapy,  and  has  revealed  that  erythromycin,  the
most  famous  macrolide  antibiotic,  could  inhibit
chemotaxis and  generation  of  inflammatory  media-
tors such as O–
2 and H2O2 by neutrophils when the
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agent.8 Furthermore,  oral  administration  of  roxi-
thromycin (RXM) once a day for more than 3 weeks
has been shown to be able to suppress the ability of
lymphocytes  to  produce  inflammatory  cytokines,
such as interleukin (IL)-1b, in response to mitogenic
and  antigenic  stimulation.9,10 Judging  from  these
reports,  there  is  a  possibility  that  macrolide  anti-
biotics  inhibit  the  development  of  inflammatory
responses and result in favorable modification of the
clinical  conditions  of  patients  with  inflammatory
diseases.
There  is  enough  evidence  that  T  cells  play  a
central role in initiation, driving and maintenance of
inflammatory  responses  through  the  secretion  of
several  types of  cytokines.9,11 It is now also estab-
lished  that  the  CD28/B7  co-stimulatory  pathway  is
essential for T-cell activation, proliferation and cyto-
kine secretion.12,13 A number of studies have clearly
demonstrated that expressions of the co-stimulatory
molecules  (CD80  and  CD86)  on  peripheral  blood
leukocytes from patients with inflammatory diseases
were  upregulated  compared  with  normal  sub-
jects.14–16 It  is  also  reported that CD80  and  CD86
expressions  on  B  cells  were  enhanced  when  the
cells  prepared  from  atopic  patients  and  pollinosis
subjects  were  stimulated  with  specific  antigen  in
vitro.17,18 In  mouse  models  for  inflammatory  dis-
eases,  treatment  of  mice  with  anti-CD80  and  anti-
CD86  monoclonal  antibodies  (mAbs)  reduced  sev-
eral parameters of  inflammatory  responses such as
eosinophilia  and  IgE  hyper-production.19–21
Although  these  reports  suggest  the  importance  of
co-stimulatory  molecules  in  the  induction  and  the
development of the inflammatory diseases, there is
little information about the influence of RXM on co-
stimulatory  molecule  expressions.22 The  present
study,  therefore,  was  undertaken  to  examine
whether RXM could modulate the expression of co-




Specific pathogen free male BALB/c mice, 5 weeks of
age, were purchased from  Charles River  Japan Inc.
(Atsugi,  Japan). After  arrival  at  our  university,  they
were  kept  in  filter  (0.2mm)-barriered  cages,  and
provided  with  autoclaved  food  and  tap  water  ad
libitum throughout  the  experiments  to  prevent
unwanted  microbiological  infection.  Each  experi-
mental and control group consisted of five mice. All
animal  experimental procedures were  approved by
the  Animal  Care  and  Use  Committee  of  Showa
University, and were carried out in accordance with
the guidelines of the Physiological Society of Japan.
Monoclonal antibodies (mAbs)
mAbs  to  block  T-cell  stimulation  were  anti-mouse
CD80 and CD86 antibodies (PharMingen, San Diego,
CA,  USA). All  thesemAbs  were  used  free  of  NaN3.
ThemAbs used for flow cytometric analysis were as
follows; fluorescein isothiocyanate (FITC)-conjugated
anti-mouse  CD40mAb  (hamster  IgM),  FITC-conju-
gated  anti-mouse  CD80mAb  (hamster  IgG),  FITC-
conjugated  anti-mouse  CD86mAb  (rat  IgG2a)  and
anti-mouse  CD16/CD32mAb. They  were  purchased
from PharMingen and contained 0.1% NaN3.
Agents
RXM was kindly donated from Aventis Pharm Co., Ltd.
(Tokyo,  Japan)  as  preservative-free  pure  powders.
RXM  was  dissolved  in  100%  methyl  alcohol  at  a
concentration of  20.0mg/ml  and then diluted with
the culture medium at a concentration of 100mg/ml.
This  solution  was  sterilized  by  passing  through  a
0.22mm filter and stored as a stock solution at 4°C
until used. All dilutions used in in vitro study were
prepared from  this stock solution. For in vivo use,
RXM dissolved in 100% methyl alcohol (20.0mg/ml)
was diluted with sterile saline to give a concentration
of 250mg/ml.
Immunization
Mice  were  immunized  by  intraperitoneal  injection
with 8.0mg of hemocyanin (Sigma Chemical Co., St
Louis,  MO,  USA)  absorbed  to  4.0mg  of  aluminum
hydroxide (Wako Chemical Co., Ltd., Osaka, Japan) in
a volume of 0.5ml of saline.
Treatment of mice with RXM
Mice  were  treated  orally  with  RXM  at  a  dose  of
2.5mg/kg once a day for 4 or 8 weeks, starting 7 days
after the immunization.
Cell preparation
Spleen  was  removed  from  mice  killed  under  ether
anesthesia.  The  organs  were  pressed  through
60-gauge stainless steel meshes into saline. The cells
were washed once with saline and resuspended in
Tris-buffered ammonium chloride (17 mM Tris–HCI,
0.73% NH4CI; pH 7.6) to lyse red blood cells. After
passing  through  a  200-gauge  steel  sieve,  the  cells
were  washed  five  times  with  RPMI-1640  medium
(WAKO  Chemical)  supplemented  with  10%  heat-
inactivated fetal  calf  serum  (SIGMA  Chemical)  at  a
concentration  of  5  ´ 106 cells/ml.  In  the  case  of
experiments using purified T cells and B cells, these
cells  were  separated  from  spleen  cells  using  a
magnetic  cell  separator  (Miltenyi  Biotec  GmbH,
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ously.23The purity of cells was checked by incubating
separated cells  with  FITC-conjugatedmAb  to  CD90
(PharMingen).  Fluorescence  microscopic  examina-
tion  revealed  that  the  percentage  of  contaminated
cells in each fractionated populations was less than
2%, respectively. CD90-positive cells were used as T
cells and CD90-negative cells as B cells.
Cell culture and culture supernatant
To examine blastic activity of the cells to antigenic
stimulation, cells prepared from  mice 10 days after
immunization (1 ´ 105 cells/100ml) were added to the
wells  of  96-well  flat-bottomed  microtiter  plates,
which contained various concentrations of RXM and
100.0 mg/ml  of  hemocyanin  in  a  final  volume  of
200ml. The plates were maintained for 72h at 37°C in
a humidified atmosphere with 5% CO2. Cell prolifera-
tion was assessed by adding 1.0mCi of 3H-thymidine
for  the  final  8h  of  the  culture.  Incorporation  of
3H-thymidine was  measured with  a  Packard Tricarb
liquid  scintillation  counter  and  the  results  were
expressed  as  mean  counts  per  minute  (CPM)  ±
standard error of triplicate cultures. To examine the
effects of anti-CD80 and anti-CD86mAbs on antigen-
induced cell proliferation, eachmAb was added at the
concentration of 5.0mg/ml to the cultures from the
beginning. In the case of examining blastic activity of
cells  to  anti-CD3mAb  stimulation,  100ml  of  T-cell
suspension (2 ´ 105 cells) was introduced into each
well  of  96-well  flat-bottomed  plates,  which  was
coated with  20.0mg/ml  ofmAb  to  mouse  CD3« as
previously  described.23,24 Various  concentrations of
RXM were then added in another 100ml to give a total
volume of 200ml. The cell proliferation was assessed
in a similar manner. For examination of the influence
of RXM on co-stimulatory molecule expressions, cell
suspensions  (5  ´ 105 cells)  were  dispensed  into
24-well  plates that contained 0.5ml  of 5.0mg  RXM
and 100.0 mg/ml antigen. The plates were maintained
for 24h at 37°C in a humidified atmosphere with 5%
CO2 in  air. The  cells  were  then  collected,  washed
twice with saline, resuspended and stored on ice until
processed.  To  prepare  culture  supernatants,  cells
were cultured for 24h in a similar manner. Culture
supernatants were  obtained after  pelleting  cells  by
centrifugation at 3000rpm for 10min at 4°C.
Assay for cytokines
IL-4 and IL-5 concentrations in culture supernatants
were assayed using the commercially available mouse
cytokine enzyme linked immunosorbent assay (ELISA)
Test Kits (R & D systems, Inc., Minneapolis, MN, USA).
The ELISA was coined out in duplicate according to the
manufacturer’s  protocol.  The  minimum  detectable
level of each ELISA kit is less than 2pg/ml.
Assay for serum IgE
The  blood  was  obtained  from  mice  by  cardiac
puncture under ether anesthesia 24h after the second
immunization (4 or 8 weeks after the first immuniza-
tion). After clotting, the serum was obtained, and total
serum  IgE  levels  were  measured  in  duplicate  by
mouse IgE enzyme immunoassay kits (YAMASA Co.
Ltd., Chiba, Japan) according to the manufacturer’s
recommended  procedures.  The  sensitivity  of  this
assay kit is less than 5ng/ml.
Flow cytometry
The purified cultured B cells were treated with 1.0mg
of  anti-mouse CD16/CD32mAb for 5min  at 4°C to
block non-specific  Fc  receptor-mediated binding  of
antibodies. Pre-treated cells were then stained with
either FITC-conjugatedmAb to CD40, CD80 or CD86
for 25min  at 25°C. After washing once, cells were
suspended  in  saline,  and  assayed  for  fluorescent
intensity  on  cells  using  a  flow  cytometer  (EPICS
ALTRA™;  Beckman  Coulter  Company,  Miami,  FL,
USA)
Statistical analysis
Analysis  of  variance,  combined  with  Fisher’s  PLSD
test,  was  performed  to  determine  the  statistical
significance.
Results
Influence of RXM on spleen cell activation
The  first  set  of  experiments  was  undertaken  to
examine  the  influence  of  RXM  on  cell  activation
induced by in vitro stimulation with antigen. Spleen
cells prepared from five individual mice immunized
with hemocyanin 10 days before were cultured with
100.0 mg/ml  of  hemocyanin  and  various  concentra-
tions  of  RXM  for  72h. As  shown  in  Fig.  1A,  low
concentrations of RXM did not affect the proliferative
responses of spleen cells to hemocyanin stimulation.
However,  addition of  RXM  to the cultures  at more
than 5.0mg/ml caused a statistically significant inhibi-
tion of the proliferative responses of spleen cells (Fig.
1A).  The  next  experiments  were  undertaken  to
examine whether the suppressive activity of RXM on
antigen-induced cell activation was also observed in
cells stimulated by anti-CD3mAb. Immunized splenic
T cells were cultured with immobilizedmAb in the
presence of various concentrations of RXM for 72h.
The data in Fig. 1B show that RXM did not interfere
with the proliferative response of T cells even when
the cells were cultured with 10.0mg/ml of RXM. The
third experiments were designed to assess the influ-
ence  of  RXM  on  antigen-specific  cell  activation by
examining the cytokine levels in culture supernatants.
Inhibitory action of RXM
Mediators of Inflammation · Vol 11 · 2002 237M. Suzuki et al.
238 Mediators of Inflammation · Vol 11 · 2002
FIG. 1. Influence of RXM on antigen-induced proliferative response of splenic lymphocytes. BALB/c mice were immunized by
intraperitoneal injection with 8.0mg/ml of hemocyanin KLH absorbed to 4.0mg of aluminum hydroxide in a volume of 0.5ml.
Spleen cells (1 ´ 10
5 cells/0.1ml) prepared from mice 10 days later were cultured in the presence of various concentrations of
RXM for 72h, which were stimulated with 100.0mg/ml of KLH (A). Splenic T cells (2 ´ 10
5 cells/0.1ml) were also cultured with
immorbilized  anti-CD3« monoclonal  antibody  in  the  presence  of  various  concentrations  of  RXM  for  72h  (B).  The  cell
proliferation was assessed by measuring incorporation of 1.0mCi of 
3H-thymidine for 8h. The results are expressed as mean
cpm ± standard error of five individual mice. * Significant at p < 0.05 as compared with KLH alone, ** not significant (p > 0.05)
as compared with anti-CD3 alone.
FIG. 2. Influence of RXM on cytokine production from sensitized spleen cells induced by antigenic stimulation in vitro. BALB/c
mice  were  immunized  by  intraperitoneal injection  with  8.0mg/ml  of  hemocyanin KLH  absorbed  to  4.0mg  of  aluminum
hydroxide in a volume of 0.5ml. Spleen cells (1 ´ 10
5 cells/0.1ml) prepared from mice 10 days later were stimulated with
100.0mg/ml of KLH in the presence of various concentrations of RXM for 24h. Cytokine concentrations in culture supernatants
were examined by ELISA. Data represent the mean (pg/ml) ± standard error of five individual mice. * Not significant (p > 0.05)
as compared with KLH alone, ** significant at p < 0.01 as compared with KLH alone.The data in Fig. 2 clearly show the dose-dependent
suppressive effects of RXM on IL-4 and IL-5 produc-
tion.  The  statistically  significant  suppression  was
observed when cells were cultured in the presence of
more than 5.0mg/ml of RXM. The fourth experiments
were carried out to examine the influence of block-
ade of co-stimulatory molecules on antigen-induced
spleen cell proliferation. Spleen cells prepared from
immunized mice were cultured with 100.0mg/ml of
hemocyanin and 5.0mg/ml ofmAbs. As shown in Fig.
3, addition of either anti-CD80mAb or anti-CD86mAb
into  cell  cultures  significantly  suppressed  the  pro-
liferative  response of  spleen  cells  induced  by  anti-
genic  stimulation. The suppressive  activity  of  these
two antibodies was further strengthened when two-
mAbs were added simultaneously (Fig. 3).
Influence of RXM on co-stimulatory molecule
expression in vitro
The  present  study  was  designed  to  examine  the
influence of RXM on co-stimulatory molecule expres-
sions on splenic B cells. Spleen cells prepared from
mice immunized with hemocyanin were cultured in
the  presence  of  100.0mg/ml  of  hemocyanin  and
5.0mg/ml of RXM for 24h. The cultured B cells were
stained with FITC-labeledmAbs against co-stimulatory
molecules  and  the  expression  of  CD40,  CD80  and
CD86  examined  by  flow  cytometer.  In  flow  cyto-
metry, we gated and analyzed the lymphocyte posi-
tion/population of scattered dots of cultured cells in
the display of a computer. Figure 4 shows one typical
profile  among  results  obtained  in  three  different
experiments  of  mice  immunized  by  hemocyanin.
Addition  of  RXM  into  cell  cultures  at  a  dose  of
5.0mg/ml  remarkably  suppressed  CD80  and  CD86
expressions,  which  were  enhanced  by  antigenic
stimulation  in  vitro.  RXM  also  exerted  inhibitory
effects on CD40 expression in response to antigenic
stimulation in vitro (Fig. 4).
Inhibitory action of RXM
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FIG.  3.  Suppressive  activity  of  anti-CD80  and  anti-CD86
monoclonal antibodies on antigen-induced spleen cell pro-
liferation. BALB/c mice were immunized by intraperitoneal
injection with 8.0mg/ml of  hemocyanin (KLH) absorbed to
4.0mg of aluminium hydroxide in a volume of 0.5ml. Spleen
cells prepared 10 days later were cultured with either anti-
CD80 or anti-CD86, or anti-CD80 and anti-CD86 for 72h, which
were stimulated with 100.0mg/ml of KLH. The cell prolifera-
tion was assessed by measuring incorporation of 1.0mCi of
3H-thymidine for 8h. The results were expressed as mean
cpm ± standard error of five individual mice. *Significant at
p < 0.001 as compared with KLH alone.
FIG. 4. Influence of RXM on co-stimulatory molecule expres-
sions induced by antigenic stimulation in vitro. BALB/c mice
were immunized by intraperitoneal injection with 8.0mg/ml
of hemocyanin absorbed to 4.0mg of aluminum hydroxide in
a volume of 0.5ml. Spleen cells prepared mice 10 days after
immunization  were  cultured  with  5.0mg/ml  of  RXM  and
100.0mg/ml  of  hemocyanin  for  24h.  The  expression  was
analyzed by flow cytometer: (____) cultured without antigen,
(. . . . .)  cultured  with  antigen,  (_ . . _ . . _)  cultured  with
antigen and RXM.Influence of RXM on IgE production in vivo
The  present  study  was  designed  to  examine  the
influence  of  RXM  treatment  on  IgE  production  in
immunized  mice. As  shown in  Fig.  5,  treatment of
mice with 2.5mg/kg of RXM once a day for 4 and 8
weeks caused significant inhibition of IgE production,
which was upregulated by hemocyanin immunization
(p < 0.001).
Influence of RXM on co-stimulatory molecule
expression in vivo
The final set of experiments was designed to examine
the  influence  of  RXM  on  co-stimulatory  molecule
expression  in  vivo. To  do  this,  mice  were  treated
orally with RXM (2.5mg/kg) once a day for 4 or 8
weeks. These RXM-treated mice were injected intra-
peritoneally with 8.0mg/ml of hemocyanin absorbed
to 4.0mg  of  aluminum  hydroxide, and spleen cells
were prepared from mice 24h later. Splenic B cells
were then isolated and examined for CD40, CD80 and
CD86  expressions  by  flow  cytometer.  One  typical
result of four different mice is shown in Figs 6 and 7.
As shown in Fig. 6 (left panel), CD40 expression was
markedly enhanced by antigenic stimulation in vivo,
which was suppressed by oral administration of RXM
for 4 weeks. However, CD80 and CD86 expressions
were scarcely affected by  antigenic stimulation and
RXM treatment. In a case of pre-sensitized mice (Fig.
6, right panel), in addition to CD40 expression, CD86
(but not CD80) expression was enhanced by second-
ary antigenic stimulation in vivo and these molecule
(CD40  and CD86)  expressions were suppressed by
oral RXM treatment for 4 weeks. We further examined
the influence of RXM treatment for 8 weeks on CD
molecule expressions. As shown in Fig. 7 (left panel),
antigenic stimulation in  non-sensitized mice caused
drastic  effect  on  CD40  expression,  and  this  was
suppressed by RXM treatment. The data in Fig. 7 (left
panel)  also showed that oral RXM  treatment could
suppress  CD86 (but  not CD80) expressions, which
was  clearly  enhanced  by  antigenic  stimulation  in
vivo.  In  pre-sensitized  mice,  antigenic  stimulation
caused enhancement of all CD molecule expressions
examined, and they were clearly suppressed by RXM
treatment (Fig. 7, right panel).
Discussion
Several studies have shown that long-term administra-
tion of macrolide antibiotics can favorably modify the
clinical  condition  of  inflammatory  diseases.1–7
Although  the  precise  therapeutic  mechanisms  of
macrolides are not well understood, it is speculated
that the efficacy of macrolide treatment is owing to
anti-inflammatory rather than anti-bacterial effects of
the agents.8–10 Many of the steps in the inflammatory
cascade  are  reported  to  be  controlled  by  soluble
regulatory molecules (serotonin, histamine and leuko-
triene,  etc.)  known  as  inflammatory  or  chemical
mediators.11 Furthermore,  much  evidence  clearly
shows that T  cells  play  a  pivotal  role  in  initiation,
driving  and  maintenance  of  all  these processes  by
elaboration of several types of cytokines.9–11 There is
now also the established concept that the CD28/B7
co-stimulatory pathway is essential for full activation
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FIG. 5. Influence of oral RXM treatment on IgE production in vivo. BALB/c mice were immunized by intraperitoneal injection
with  8.0mg/ml  of  hemocyanin absorbed  to  4.0mg of  aluminum hydroxide in  a  volume of  0.5ml.  The mice  were orally
administered with 2.5mg/kg of RXM once a day for 4 or 8 weeks starting 7 days after immunization. Serum IgE levels were
assayed by ELISA. Data represent the mean (ng/ml) ± standard error of five individual mice. NI, Non-immunized control; I,
immunized. * Not significant (p > 0.05) as compared with control, ** significant at p < 0.001 as compared immunized mice.of T cells, including proliferation and cytokine secre-
tion.12,13Yet the action of RXM on the co-stimulatory
pathway  is  poorly  understood.22 To  examine  the
influence of RXM on the co-stimulatory pathway, it
was first tested on the response of lymphocytes to in
vitro antigenic  stimulation  by  examining  cell  pro-
liferation and cytokine production. The present data
(Figs 1 and 2) clearly show the antigen-specific, but
not  non-specific,  inhibitory  effects  of  RXM  on  cell
activation.  It  is  also  suggested  that  the  inhibitory
action  of  RXM  on  cell  activation  is  not  due  to
cytotoxic effects of the agent to splenic T cells, since
non-specific cell activation induced by anti-CD3mAb
stimulation is not influenced  by  RXM  (Fig.  1B). An
optimal antigen-specific T-cell activation requires two
distinct signals. Activation of T cells by signals through
the T-cell receptor in the presence of co-stimulatory
signals  results  in  T-cell  clonal  expansion  and  the
induction of effector functions such as the production
of cytokines.12–15 On the contrary, the interaction of
T cells with antigen in the absence of co-stimulatory
signals  is  not  a  neutral  event  but,  rather,  leads  to
induced unresponsiveness or to cell death.12,13 It is
reported that RXM not only interfered with, but also
Inhibitory action of RXM
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FIG. 6. Influence of oral RXM treatment for 4 weeks on co-stimulatory molecule expressions induced by antigenic stimulation
in  vivo.  BALB/c  mice  were  immunized by  intraperitoneal injection  with 8.0mg/ml  of  hemocyanin absorbed  to  4.0mg  of
aluminum hydroxide in a volume of 0.5ml. The mice were orally administered with 2.5mg/kg of RXM once a day for 4 weeks
starting  7  days  after  immunization. Splenic  B  cells  were  prepared  from  mice  24h  after  challenging immunization. The
expression  was  analyzed  by  flow  cytometer:  (____)  non-treated  and  non-challenged  control,  (. . . . .)  non-treated  and
challenged, (_ . . _ . . _) treated and challenged. Left panels, non-immunized mice; right panels, immunized mice.enhanced, the capacity of activated antigen present-
ing cells C to present antigenic properties.25 These
reports and the data in Fig. 3 may suggest that RXM
suppressed co-stimulatory molecule expressions and
resulted in inhibition of cell activation by antigenic
stimulation in vitro. Therefore, we next examined the
influence of RXM on co-stimulatory molecule expres-
sions on splenic  B cells. The present results clearly
show that RXM could suppress the expression of co-
stimulatory molecules CD80 and CD86 on sensitized
splenic  B  cells,  which  were  enhanced by  in  vitro
stimulation with antigen (Fig. 5).
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FIG. 7. Influence of oral RXM treatment for 8 weeks on co-stimulatory molecule expressions induced by antigenic stimulation
in  vivo.  BALB/c  mice  were  immunized by  intraperitoneal injection  with 8.0mg/ml  of  hemocyanin absorbed  to  4.0mg  of
aluminum hydroxide in a volume of 0.5ml. The mice were orally administered with 2.5mg/kg of RXM once a day for 8 weeks
starting  7  days  after  immunization. Splenic  B  cells  were  prepared  from  mice  24h  after  challenging immunization. The
expression  was  analyzed  by  flow  cytometer:  (____)  non-treated  and  non-challenged  control,  (. . . . .)  non-treated  and
challenged, (_ . . _ . . _) treated and challenged. Left panels, non-immunized mice; right panels, immunized mice.De Boer et al. showed that CD80 could act as a co-
stimulatory molecule for the production of IL-4 and
IL-5, which are essential cytokines for development
and  maintenance  of  inflammatory  diseases,  from
human  peripheral  blood  T  cells  in  response  to
stimulation withmAb directed at the T-cell receptor.26
It is also showed that CTLA-4 immunoglobulin fusion
protein (CTLA-4Ig), a blocker of CD28/B7 co-stimula-
tion, could block allergen-specific proliferation and T
helper cell type 2 cytokine (IL-4 and IL-5) production
by  peripheral blood mononuclear cells from atopic
donors.27 In support of these in vitro studies, several
in vivo studies have noted that blockade of CD28/B7
co-stimulation preferentially inhibits Th2 cell respon-
ses,  while  leaving T  helper  cell  type  1  responses
intact.28–30 With  regard  to  the  influence  of  CD80/
CD86 on effector cell (mainly eosinophils) functions,
a lot of reports show that intranasal administration of
CTLA4Ig inhibited eosinophil accumulation in lungs
and airway tracts induced by aerosol provocation of
allergen.19,31,32 It is also reported that airway admin-
istration  of  anti-CD86mAb  inhibited  eosinophil
influx,  IgE  production,  and  T  helper  cell  type  2
cytokine  secretion  comparable  in  magnitude  with
that observed with CTLA-4Ig.19 Judging  from  these
reports, the present results (Fig. 4) suggest that RXM
exerts an attenuating effect on inflammatory diseases
through inhibition of co-stimulatory molecule expres-
sions. However, before drawing the conclusion that
oral RXM treatment suppress co-stimulatory molecule
expressions and results in favorable modification of
the inflammatory diseases, it is necessary to examine
whether oral administration of RXM could inhibit co-
stimulatory  molecule  expressions  in  response  to
antigenic stimulation in vivo.
IgE-dependent stimulation of tissue mast cells and
their  circulating  counterparts,  basophils,  is  well
known to constitute one of the major effector systems
of allergic diseases that reflect the immunologically
induced  inflammatory  responses  in  the  organ  or
tissue involved. It is proposed that the prevention or
suppression of IgE antibody formation to allergens is
one of the fundamental treatments of inflammatory
diseases  including  hay  fever,  allergic  asthma  and
urticaria.33 IgE synthesis is recognized to be depend-
ent on a complex process involving several cellular
and molecular interactions.34,35The initial step for the
development of IgE-producing plasma cells is «-germ-
line transcription by IL-4 and IL-13.34 The second is
provided by engagement of CD40 and CD40 ligand,
which is important for switch recombination to IgE
synthesis in B cells.35 These reports suggest that the
suppressive  effects  of  RXM  on  CD40  expressions
might be contribute, in part, to the therapeutic mode
of action of RXM on inflammatory diseases.
Although  the  present  results  clearly  suggest  that
RXM inhibits co-stimulatory molecule expressions on
splenic lymphocytes in response to antigenic stimula-
tion in vitro and in vivo, the precise mechanisms are
not understood at present. Pharmacological studies
revealed that erythromycin36 and  RXM  (M.  Suzuki,
unpublished  observations  2001)  prevent  calcium
cation influx into cells, resulting in reduced permea-
bility  of  the  cell  membrane  and  in  inhibition  of
expression of protein synthesized in the cytosol. It is
also reported that erythromycin increases the intra-
cellular  cyclic  adenosine  monophosphate  (cAMP)
level.37 Elevation  of  the  intracellular  cAMP  level
elaborates an important downregulatory signal in the
release  of  proteins  synthesized  in  the  cytosole.38
From these reports, it is possible that RXM prevents
accumulation of the calcium cation in the cytosol and
enhances  the  intracellular  cAMP  level,  resulting  in
inhibition  of  CD  molecule  expressions.  Further
experiments are needed to clarify this point.
Inhibitory action of RXM
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